Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 4, 2005, Pages 327-334

  Whang, P G ^a   Gamradt, S C ^a   Gates, J J ^a   Lieberman, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone metastasis; Bortezomib; Prostate adenocarcinoma; Proteasome inhibitor; Ubiquitin proteasome

Indexed keywords

BORTEZOMIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; TIME;

ANIMALS; BONE NEOPLASMS; BORONIC ACIDS; CELL DIVISION; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 30544448058     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500823     Document Type: Article

References (50)

1. Jemal A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Koeneman K, Yeung F, Chung L. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39: 246-261.
3. Glaves D. Mechanisms of metastasis: Prostate cancer. Prog Clin Biol Res 1987; 239: 329-345.
4. Chiarodo A. National Cancer Institute round table on prostate cancer: future research directions. Cancer Res 1991; 51: 2498-2505.
5. Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
6. Coux O, Tanaka K, Goldberg AL. Structure and function of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-847.
7. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 503-533.
8. Garrett IR et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771-1782.
9. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from Archaebacteria to drug development. Chem Biol 1995; 2: 503-508.
10. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996; 274: 1652-1659.
11. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997; 9: 788-799.
12. Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998; 77: 448-455.
13. Adams J et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
14. Sunwoo JB et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-1428.
15. Hideshima T et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2000; 61: 3071-3076.
16. Bours V et al. The NF-kappa B transcription factor and cancer: High expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994; 47: 145-149.
17. Oikawa T et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-248.
18. Um JH et al. Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene 2001; 20: 6048-6056.
19. Nawrocki ST et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1: 1243-1253.
20. Kordes U et al. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
21. Ni H et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: Downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001; 115: 279-286.
22. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-784.
23. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-787.
24. Van Antwerp DJ et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-789.
25. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-785.
26. Cusack JC, Liu R, Baldwin AS. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist Updat 1999; 2: 271-273.
27. Delic J et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77: 1103-1107.
28. Cusack Jr JC et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-3540.
29. Soligo D et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Hematol 2001; 113: 126-135.
30. Russo SM et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183-193.
31. Ma MH et al. The proteasome inhibitor PS-341 markedly enhances the sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
32. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062-1075.
33. Frankel A et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6: 3071-3076.
34. Orlowski RZ et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-4427.
35. Aghajanian C et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-2511.
36. Davis NB et al. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 2004; 22: 115-119.
37. Richardson PG et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
38. Kane RC, Bross PE, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508-513.
39. Papandreou CN et al. Phase I trial with proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-2121.
40. Williams S et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2: 835-843.
41. Lin HK et al. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002; 277: 36570-36576.
42. Kaighn M et al. Establishment and characterization of a human prostate carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
43. Craft N et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59: 5030-5036.
44. Lee Y et al. Use of zoledronate to treat osteoblastic vs osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002; 62: 5564-5570.
45. Lee Y et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003; 21: 62-72.
46. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
47. Zhang J et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-1244.
48. Yonou H et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003; 63: 2096-2102.
49. Whang PG et al. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005; July 5 (Epub ahead of print).
50. Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14.